An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

Roche

Status: Completed

Conditions: Colorectal Cancer

Treatments: Drug: Bevacizumab; Drug: Chemotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT01712347

ML28233

Details and patient eligibility

About

This multicenter observational study will evaluate the efficacy and safety of first-line bevacizumab (Avastin) in combination with fluoropyrimidine-based chemotherapy in participants with metastatic colorectal cancer (mCRC). Participants for whom the treating physician has decided to initiate first-line fluoropyrimidine based chemotherapy in combination with bevacizumab will be observed for approximately 4 years.

Enrollment: 351 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with histologically confirmed metastatic colorectal cancer who will receive bevacizumab in combination with first-line fluoropyrimidine-based chemotherapy

Exclusion criteria

• Participants not qualified for bevacizumab treatment according to the local label

Trial design

351 participants in 1 patient group

mCRC Participants

Description:

mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.

Treatment:

Drug: Chemotherapy

Drug: Bevacizumab